26.06.2018
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 refocuses R&D activities and implements cost reduction program in Scandinavia
DGAP-News: Vita 34 AG / Key word(s): Miscellaneous
Vita 34 refocuses R&D activities and implements cost reduction program in
Scandinavia
26.06.2018 / 14:00
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Vita 34 refocuses R&D activities and implements cost reduction program in
Scandinavia
- Focusing of R&D activities on the identification, isolation and
characterization of immune cells from umbilical cord blood
- Procurement of stem cells from adipose tissue for perspective use in the
field of aesthetic medicine (lipofilling)
- Cost reduction program in Scandinavia to be implemented
Leipzig, 26 June 2018 - Vita 34 AG (ISIN: DE000A0BL849, WKN: A0BL84), the
second largest stem cell bank in Europe, continues to work on the
implementation of its Vision 2021. All Group activities will be reviewed for
their sustainable contribution to short, medium and long-term earnings
improvement.
In the field of Research & Development (R&D), Vita 34 will concentrate on
two focus areas in the future: in the core market of umbilical cord blood
the identification, isolation and characterization of immune cells will move
into focus. The future market of personalized cell therapy offers attractive
business areas that will expand and round off the business model in the
future. As part of its portfolio expansion, Vita 34 will also drive along
the further development of the Adipovita product. Based on Adipovita, which
makes it possible to obtain stem cells from adipose tissue from adults, Vita
34 plans to position itself in the area of lipofilling in the medium term,
opening up to the attractive aesthetic medicine market. Due to insufficient
commercialization opportunities, development projects in the area of plant
stem cells, resulting from the acquisition of BioPlanta in 2011, will be
discontinued.
In addition, from July 2018, Vita 34 will cease its active marketing
activities in Denmark, Sweden and Norway. After weighing up economic and
social aspects, the Management Board decided to take this step after Vita 34
was unable to establish a sustainable positive new customer business through
its subsidiary Vita 34 ApS since entering the Scandinavian market in 2015.
On the basis of a careful review, there was no prospect of generating a
sustainable profit surplus with the current orientation of the business
activities. This is largely due to the special market conditions in the
Scandinavian region.
The Danish subsidiary Vita 34 ApS will be remained and will continue the
storage business of the existing units. As a result, the Scandinavian
subsidiary will contribute a sustained positive EBITDA of around EUR 0.5
million to Group EBITDA starting in 2019. Based on the business development
in 2017, this corresponds to an increase in earnings at group level of
around EUR 1.0 million.
"Since the management change in mid-2017, we have been reviewing all our
activities for their contribution to the current and future profitability of
the Group," explains Dr. Wolfgang Knirsch, CEO of Vita 34 AG. "Over the past
few months, we have intensively examined our structures in the area of R&D
and in Sales for sustainability. With the adjustments that have now been
made, we will be much better positioned in the future and can invest our
resources in a much more targeted manner. "
Against the background of the effects of savings and one-time expenses
arising from the measures taken in the current financial year, the
Management Board of Vita 34 AG remains unchanged in its current outlook for
the 2018 financial year.
Further information on Vita 34 AG and its product range is available on the
company's website at www.vita34.de.
Contact:
Ingo Middelmenne
Investor Relations
Vita 34 AG
Phone: +49 (0341) 48792 - 0
Mobile: +49 (0174) 9091190
Email: [email protected]
Company Profile
Vita 34 was founded in Leipzig in 1997 as the first private stem cell bank
in Europe and, as a complete provider of cryo-preservation services, offers
collection, logistics, preparation, and storage of stem cells from umbilical
cord blood and tissue. Stem cells are a valuable base material for medical
cell therapy and are kept alive at temperatures of minus 180 degrees
Celsius, in order to be available for use in a treatment if needed. More
than 200,000 customers from Germany and 28 other countries have already
provided for their children's future with a stem cell deposit at Vita 34.
---------------------------------------------------------------------------
26.06.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
698759 26.06.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V